A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors

被引：0
|
作者：
Ji, Dongmei
Weitao, Yao
Tong, Xiangmin
Zhang, Chenping
Wang, Feng
Chen, Zhendong
Zhou, Yuhong
Li, Zhendong
Deng, Yaotiao
Huang, Gang
Tao, Zhiwei
Zheng, Yulong
Wang, Gang
Liu, Guowen
Chen, Jing
Niu, Xiaohui
Yang, Jilong
Pang, Weijia
Zhao, Min
Hu, Xichun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Orthoped, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] ZheJiang Prov Peoples Hosp, Dept Hematol, Hangzhou, Peoples R China
[5] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[7] Anhui Med Univ, Affiliated Hosp 2, Dept Oncol, Hefei, Peoples R China
[8] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China
[9] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[10] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[11] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Orthoped & Soft Tissue, Changsha, Peoples R China
[12] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Univ Sci & Technol China, Affiliated Hosp 1, Hefei, Peoples R China
[15] Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China
[16] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China
[17] Beijing Jishuitan Hosp, Beijing, Peoples R China
[18] Beijing Jishuitan Hosp, Beijing, Peoples R China
[19] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[20] ImmVira Co Ltd, Shenzhen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors
    Hu-Lieskovan, S.
    Patnaik, A.
    Eisenberg, P.
    Sachdev, J.
    Weise, A.
    Kaufman, D. R.
    Aromin, I.
    West, B. L.
    Tong, S.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 7 - 7
  • [22] A phase 1/2 study of RTX-224, an engineered red blood cell expressing 4-1BB ligand and membrane-bound IL-12, for the treatment of patients with select advanced solid tumors
    Spira, Alexander I.
    Johnson, Melissa Lynne
    Ren, Ai
    Sundaresan, Varsha
    Verdon, Ines
    Turka, Laurence
    Elloul, Sivan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.
    Wainberg, Zev A.
    Eisenberg, Peter D.
    Sachdev, Jasgit C.
    Weise, Amy M.
    Kaufman, David Ross
    Hutchinson, Marguerite
    Tong, Sandra
    Aromin, Ireene
    Hu-Lieskovan, Siwen
    Patnaik, Amita
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [24] EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Price, Timothy
    Chawla, Sant
    Falchook, Gerald
    Prenen, Hans
    Lugowska, Iwona
    Subbiah, Vivek
    Monzon, Jose
    Ozawa, Yuichi
    Arkenau, Tobias
    Lima, Caio Rocha
    Kuboki, Yasutoshi
    Nishina, Tomohiro
    Hui, Mun
    Rasmussen, Erik
    Wong, Hansen
    Najmi, Saltanat
    Sadraei, Nooshin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A245 - A245
  • [25] VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors
    Powell, S. F.
    Patel, M. R.
    Merchan, J.
    Strauss, J.
    Cripe, T. P.
    Old, M. O.
    Diaz, R. M.
    Reckner, M.
    Brunton, B.
    Packiriswamy, N.
    Upreti, D.
    Suksanpaisan, L.
    Vandergaast, R.
    Khan, R.
    Russell, S. J.
    Peng, K. W.
    Bexon, A. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors
    Harrington, Kevin Joseph
    Sacco, Joseph J.
    Olsson-Brown, Anna Claire
    Chan, Tze Y.
    Nenclares, Pablo
    Leslie, Isla
    Saleem, Imran
    Bommareddy, Praveen
    Ahlers, Christoph Matthias
    Coffin, Robert S.
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, PD-1 antibody x IL-21 mutein bifunctional fusion protein, in patients with advanced solid tumors.
    Durm, Greg
    Frentzas, Sophia
    Rasmussen, Erik
    Najmi, Saltanat
    Sadraei, Nooshin Hashemi
    CANCER RESEARCH, 2021, 81 (13)
  • [28] AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale
    Santa Gadea, Omar Saavedra
    Christenson, Eric
    El-Khoueiry, Anthony B.
    Cervantes, Andres
    Raab, Christa
    Gaertner, Ulrike
    Pietzko, Kerstin
    Hintzen, Gabriele
    Ravenstijn, Paulien
    Morales-Espinosa, Daniela
    Suzanne Lopez, Juanita
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
    Bai, X.
    Chen, Y.
    Chen, Y.
    Liang, X.
    Wang, H.
    Sun, Y.
    Chu, Q.
    Pan, Y.
    Cui, J.
    Fang, J.
    Zhang, W.
    Xu, Q.
    Zhang, J.
    Liu, X.
    Dai, G.
    Kang, L.
    Li, N.
    Fang, M.
    Zhou, H.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 681 - 682
  • [30] PHASE 1/2 STUDY OF SUBCUTANEOUSLY ADMINISTERED ALKS 4230, A NOVEL ENGINEERED CYTOKINE, AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB, IN PATIENTS WITH ADVANCED SOLID TUMORS: ARTISTRY-2
    Powderly, John
    Carthon, Bradley
    Ernstoff, Marc
    Olszanski, Anthony
    Wrangle, John
    Shields, Anthony
    Piha-Paul, Sarina
    Curtis, Kelly
    Bidollari, Ilda
    Du, Yangchun
    Sun, Lei
    Putiri, Emily
    Wang, Yan
    Losey, Heather
    Dezube, Bruce
    Dezube, Bruce
    Vaishampayan, Ulka
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A227 - A227
12345